［1］XIONG Bei，ZUO Xuelan，NIE Yanbo，et al.Correlation of chromosome karyotype with dysplasia in myelodysplastic syndrome［J］.Modern Oncology，2017，25(23)：3835-3839.［熊蓓，左学兰，聂彦博，等.MDS病态造血与染色体核型的相关性研究［J］.现代肿瘤医学，2017，25(23)：3835-3839.］
［2］XIAO Zhijian.Decitabing in myelodysplastic symdromes：the current status and future［J］.Chinese Journal of Hematology，2014，35(3)：185-186.［肖志坚.地西他滨治疗骨髓增生异常综合征-规范和探讨在我国的临床应用［J］.中华血液学杂志，2014，35(3)：185-186.］
［3］Gotoh A.Treatment for myelodysplastic syndrome：With a focus on the low-risk group［J］.Rinsho Ketsueki，2017，58(10)：1951-1959.
［4］ZHANG ZN，SHEN T.Blood disease diagnosis and curative effect standard［M］.Beijing：Science Press，2008：106-134.［张之南，沈悌.血液病诊断及疗效标准［M］.北京：科学出版社，2008：106-134.］
［5］Li H，Wang L，Wu Y，et al.Very-low-dose decitabine is effective in treating intermediate-or high-risk myelodysplastic syndrome［J］.Acta Haematol，2017，138(3)：168-174.
［6］Gangat N，Patnaik MM，Tefferi A.Myelodysplastic syndromes：Contemporary review and how we treat［J］.Am J Hematol，2016，91(1)：76-89.
［7］Mawad R，Becker PS，Hendrie P，et al.Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS［J］.Br J Haematol，2016，172(2)：238-245.
［8］Daver N，Kantarjian H，Ravandi F，et al.A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome［J］.Leukemia，2016，30(2)：268-273.
［9］LI Guang，REN Jingjing，ZHANG Yunjie，et al.Clinical observation of decitabine combined with dose reduced IAG regimen in treatment of moderate-high risk myelodysplastic syndrome and acute myeloid leukemia［J］.Modern Oncology，2017，25(18)：2985-2989.［李光，任婧婧，张韵洁，等.地西他滨联合减量IAG方案治疗中高危骨髓增生异常综合征及其转化急性髓系白血病的临床观察［J］.现代肿瘤医学，2017，25(18)：2985-2989.］
［10］TANG Yuanyan，ZHANG Liming，ZHANG Jiangzhao，et al.Clinical observation of microtransplantation combination with induction chemotherapy in treatment for elderly patients with acute myeloid leukemia［J］.Modern Oncology，2017，25(14)：2309-2311.［唐元艳，张利铭，张江召，等.微移植联合化疗治疗老年急性髓系白血病临床观察［J］.现代肿瘤医学，2017，25(14)：2309-2311.］
［11］Guo M，Hu KX，Liu GX，et al.HLA-mismatched stem-cell microtransplantation as postremission therapy for acute myeloid leukemia：long-term follow-up［J］.J Clin Oncol，2012，30(33)：4084-4090.
［12］Hu KX，Sun QY，Guo M，et al.A study of human leukocyte antigen mismatched cellular.Therapy (stem cell microtransplantation) in high-risk myelodysplastic syndrome or transformed acute myelogenous leukemia［J］.Stem Cells Transl Med，2016，5(4)：524-549.
［13］Ai HS，Sin QY.Comments on HLA-mismatched stem-cell microtransplantation as postremission therapy for acute myeloid leukemia：Lng-term follow-up［J］.J Clin Hematol，2015，28(5)：367-369.
［14］Wang L，Du F，Wang H，et al.Cooperation of CD4+T cells and CD8+T cells and release of IFN-γ are critical for antileukemia responses of recipient mice treated by microtransplantation［J］.Exp Ther Med，2018，15(2)：1532-1537.